Literature DB >> 22215266

Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.

Amit G Singal1, Adam Yopp, Celette S Skinner, Milton Packer, William M Lee, Jasmin A Tiro.   

Abstract

BACKGROUND: Although surveillance for hepatocellular carcinoma (HCC) is recommended in high-risk patients, several studies have suggested it is being underutilized in clinical practice. The aim of our study was to quantify utilization rates for HCC surveillance among patients with cirrhosis and summarize patterns of association between utilization rates and patient socio-demographic characteristics. DATA SOURCES: We performed a systematic literature review using the Medline database from January 1990 through March 2011 and a manual search of national meeting abstracts from 2008-2010.
METHODS: Two investigators independently extracted data on patient populations, study methods, and results using standardized forms. A pooled surveillance rate with 95% confidence intervals was calculated. Pre-specified subgroup analysis was performed to find correlates of surveillance utilization.
RESULTS: We identified nine studies that met inclusion criteria. The pooled surveillance rate was 18.4% (95%CI 17.8%-19.0%). Surveillance rates were significantly higher among patients followed in subspecialty gastroenterology clinics compared to those followed in primary care clinics (51.7% vs. 16.9%, p < 0.001). Non-Caucasians and patients of low socioeconomic status had lower surveillance rates than their counterparts.
CONCLUSIONS: Utilization rates for HCC surveillance are low, although they are significantly higher among patients followed in subspecialty clinics. Current studies fail to determine why HCC surveillance is not being performed. Future efforts should focus on identifying appropriate intervention targets to increase surveillance rates and reduce socio-demographic disparities.

Entities:  

Mesh:

Year:  2012        PMID: 22215266      PMCID: PMC3378733          DOI: 10.1007/s11606-011-1952-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  25 in total

1.  Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study.

Authors:  Jessica A Davila; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2006-01       Impact factor: 11.382

2.  Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.

Authors:  Dana Sloane; Hegang Chen; Charles Howell
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival.

Authors:  Luci K Leykum; Hashem B El-Serag; John Cornell; Kyriakos P Papadopoulos
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-26       Impact factor: 11.382

5.  Racial disparities in colon cancer. Primary care endoscopy as a tool to increase screening rates among minority patients.

Authors:  Stephen C Lloyd; Norman Robert Harvey; James R Hebert; Virginie Daguise; Deloris Williams; Delores B Scott
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

Review 6.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

7.  Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer.

Authors:  Xianglin L Du; Tamra E Meyer; Luisa Franzini
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 8.  A framework for improving the quality of cancer care: the case of breast and cervical cancer screening.

Authors:  Jane G Zapka; Stephen H Taplin; Leif I Solberg; M Michele Manos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-01       Impact factor: 4.254

9.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

10.  Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer.

Authors:  Xianglin L Du; Shenying Fang; Sally W Vernon; Hashem El-Serag; Y Tina Shih; Jessica Davila; Monica L Rasmus
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

View more
  106 in total

1.  Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.

Authors:  Yolanda Rodriguez Villalvazo; Jennifer S McDanel; Lauren A Beste; Antonio J Sanchez; Mary Vaughan-Sarrazin; David A Katz
Journal:  Health Serv Res       Date:  2019-11-25       Impact factor: 3.402

2.  Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma.

Authors:  Amit G Singal; Akbar K Waljee; Nishant Patel; Emerson Y Chen; Jasmin A Tiro; Jorge A Marrero; Adam C Yopp
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

3.  Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.

Authors:  Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-31       Impact factor: 11.382

4.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

5.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

6.  A Retrospective Analysis of Surveillance Adherence of Patients after Treatment of Primary Cutaneous Melanoma.

Authors:  Jeave Reserva; Monica Janeczek; Cara Joyce; Amanda Goslawski; Hwala Hong; Feng-Ning Yuan; Neelam Balasubramanian; Laura Winterfield; James Swan; Rebecca Tung
Journal:  J Clin Aesthet Dermatol       Date:  2017-12-01

7.  Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.

Authors:  Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; Jorge A Marrero; Katharine McCallister; Hannah Fullington; Caroline Mejias; Akbar K Waljee; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm
Journal:  Hepatology       Date:  2018-12-14       Impact factor: 17.425

8.  Failure rates in the hepatocellular carcinoma surveillance process.

Authors:  Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

9.  Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection.

Authors:  Adam C Yopp; Madhu Subramanian; Mamta K Jain; John C Mansour; Roderich E Schwarz; Glen C Balch; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

Review 10.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.